News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (304 of 349). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (11 of 349). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (34 of 349). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 265 of 349 items have one.
Timeframe of 8-hour restricted eating irrelevant to weight loss
European adults with obesity who limited eating to any of three 8-hour window timeframes each day lost weight and improved cardiometabolic health.
Why it matters: European adults with obesity lost weight and improved cardiometabolic health when limiting eating to any of three 8-hour window timeframes each day.
Read at NIH National Institute on Aging → Archived copy (1 Aug 2026), Internet ArchiveA mother’s X chromosome affects learning and memory in later life
A mother’s X chromosomes may turn off key genes, accelerate brain cell aging process, and impair learning and memory later in life.
Why it matters: A mother's X chromosomes may accelerate brain cell aging and turn off key genes, impairing learning and memory in later life.
Read at NIH National Institute on Aging → Archived copy (30 Jul 2026), Internet ArchiveSenolytic therapy shows subtle impact on age-related bone health in women
An NIA-funded clinical trial investigating whether senolytics could improve bone health in older women had just subtle results.
Why it matters: An NIA-funded clinical trial investigating whether senolytics could improve bone health in older women had just subtle results.
Read at NIH National Institute on Aging → Archived copy (7 Jul 2025), Internet ArchiveScientists develop improved mouse model for studying systemic aging-related health decline
NIA scientists developed an improved mouse model to study aging-related health decline, revealing how inflammation drives organ damage.
Why it matters: NIA scientists developed an improved mouse model to study aging-related health decline, revealing how inflammation drives organ damage.
Read at NIH National Institute on Aging → Archived copy (2 Aug 2026), Internet ArchiveBright brain spots from small blood vessels could help predict Alzheimer’s risk
Bright spots in the brain called white matter hyperintensities contribute to Alzheimer’s risk. Reducing their accumulation might help slow or prevent the disease.
Why it matters: Bright spots in the brain called white matter hyperintensities contribute to Alzheimer’s risk, and reducing their accumulation might help slow or prevent the disease.
Read at NIH National Institute on Aging → Archived copy (4 Aug 2026), Internet ArchiveCassava Sciences and Its Alzheimer's Drug Are Done. The Damage Lingers.
Cassava Sciences' simufilam failed both of its Phase 3 trials (RETHINK-ALZ and REFOCUS-ALZ) in nearly 2,000 patients, missing all co-primary, secondary, and biomarker endpoints; the company ended the program. The drug's development had been dogged by allegations of falsified research.
Why it matters: Closes out a controversial, years-long saga in Alzheimer's drug development and underscores the cost to patients and the field when research-integrity concerns aren't caught earlier.
May need a subscription Based on the outlet (STAT), not a check of this article.
Read at STAT News → Archived copy (30 May 2026), Internet ArchiveFollow new items in a feed reader: Atom feed.